Press release
Complement 3 Glomerulopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma
To Know in detail about the Complement 3 Glomerulopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Complement 3 Glomerulopathy Market Forecast [https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Complement 3 Glomerulopathy Market Report:
*
The Complement 3 Glomerulopathy market size was valued approximately USD 35 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In October 2024, Novartis has reported encouraging results from the Phase III APPEAR-C3G trial, showing that Fabhalta (iptacopan), when used alongside supportive care, provided sustained improvements for patients with C3 glomerulopathy (C3G) over a 12-month period. C3G is a serious kidney disorder that frequently progresses to kidney failure within a decade of diagnosis. The APPEAR-C3G study is a Phase III, multi-center, randomized, double-blind, placebo-controlled trial aimed at evaluating the safety and effectiveness of Fabhalta, the first oral Factor B inhibitor that targets the alternative complement pathway.
*
In 2023, an estimated 5,760 diagnosed cases of Complement 3 Glomerulopathy (C3G) were reported across the seven major markets (7MM), with the United States accounting for around 60% of these cases-the highest among all countries-followed by Germany.
*
C3G is more commonly observed in adults than in the pediatric population. In Japan, around 85% of C3G cases occur in adults, while approximately 15% are seen in children.
*
In 2023, the total diagnosed prevalent population of Complement 3 Glomerulopathy (C3G) across the 7 major markets (7MM) was estimated to be approximately 5,760 cases.
*
In 2023, the diagnosed prevalent population of Complement 3 Glomerulopathy (C3G) in the United States was estimated at 3,372 individuals.
*
Key Complement 3 Glomerulopathy Companies: NovelMed Therapeutics, Apellis Pharmaceuticals, Novartis, Amyndas Pharmaceuticals, and others
*
Key Complement 3 Glomerulopathy Therapies: NM8074, Pegcetacoplan(APL-2), LNP023, AMY-10, iptacopan, and others
*
The Complement 3 Glomerulopathy epidemiology based on gender analyzed that C3GN is more prevalent than DDD
*
The Complement 3 Glomerulopathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Complement 3 Glomerulopathy pipeline products will significantly revolutionize the Complement 3 Glomerulopathy market dynamics.
Complement 3 Glomerulopathy Overview
Complement 3 glomerulopathy (C3 glomerulopathy) refers to a group of rare kidney disorders characterized by the abnormal activation of the complement system, particularly involving complement component 3 (C3). The complement system is a part of the immune system that plays a crucial role in defending the body against infections and removing damaged cells.
Get a Free sample for the Complement 3 Glomerulopathy Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market [https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Complement 3 Glomerulopathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Complement 3 Glomerulopathy Epidemiology Segmentation:
The Complement 3 Glomerulopathy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Complement 3 Glomerulopathy
*
Prevalent Cases of Complement 3 Glomerulopathy by severity
*
Gender-specific Prevalence of Complement 3 Glomerulopathy
*
Diagnosed Cases of Episodic and Chronic Complement 3 Glomerulopathy
Download the report to understand which factors are driving Complement 3 Glomerulopathy epidemiology trends @ Complement 3 Glomerulopathy Epidemiology Forecast [https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Complement 3 Glomerulopathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Complement 3 Glomerulopathy market or expected to get launched during the study period. The analysis covers Complement 3 Glomerulopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Complement 3 Glomerulopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Complement 3 Glomerulopathy Therapies and Key Companies
*
NM8074: NovelMed Therapeutics
*
Pegcetacoplan(APL-2): Apellis Pharmaceuticals
*
LNP023: Novartis Pharmaceuticals
*
AMY-10: Amyndas Pharmaceuticals
Discover more about therapies set to grab major Complement 3 Glomerulopathy market share @ Complement 3 Glomerulopathy Treatment Landscape [https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Complement 3 Glomerulopathy Market Strengths
*
The emerging market of C3G possesses several key players such as Apellis Pharmaceuticals, ChemoCentryx, and Novartis Pharmaceuticals.
*
The advent of novel biomarkers in the near future can shed some light on the pathophysiology of the disease, which may enhance the diagnosis of the indication.
Complement 3 Glomerulopathy Market Opportunities
*
Several organizations such as WeC3G, National Kidney Foundation (NKF), American Society of Nephrology (ASN), Kidney Disease: International Global Organization (KDIGO),Japanese Society of Nephrology (JSN), etc. are actively working to provide information and awareness of the disorder.
Scope of the Complement 3 Glomerulopathy Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Complement 3 Glomerulopathy Companies: NovelMed Therapeutics, Apellis Pharmaceuticals, Novartis, Amyndas Pharmaceuticals, and others
*
Key Complement 3 Glomerulopathy Therapies: NM8074, Pegcetacoplan(APL-2), LNP023, AMY-10, iptacopan, and others
*
Complement 3 Glomerulopathy Therapeutic Assessment: Complement 3 Glomerulopathy current marketed and Complement 3 Glomerulopathy emerging therapies
*
Complement 3 Glomerulopathy Market Dynamics: Complement 3 Glomerulopathy market drivers and Complement 3 Glomerulopathy market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Complement 3 Glomerulopathy Unmet Needs, KOL's views, Analyst's views, Complement 3 Glomerulopathy Market Access and Reimbursement
To know more about Complement 3 Glomerulopathy companies working in the treatment market, visit @ Complement 3 Glomerulopathy Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Complement 3 Glomerulopathy Market Report Introduction
2. Executive Summary for Complement 3 Glomerulopathy
3. SWOT analysis of Complement 3 Glomerulopathy
4. Complement 3 Glomerulopathy Patient Share (%) Overview at a Glance
5. Complement 3 Glomerulopathy Market Overview at a Glance
6. Complement 3 Glomerulopathy Disease Background and Overview
7. Complement 3 Glomerulopathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Complement 3 Glomerulopathy
9. Complement 3 Glomerulopathy Current Treatment and Medical Practices
10. Complement 3 Glomerulopathy Unmet Needs
11. Complement 3 Glomerulopathy Emerging Therapies
12. Complement 3 Glomerulopathy Market Outlook
13. Country-Wise Complement 3 Glomerulopathy Market Analysis (2020-2034)
14. Complement 3 Glomerulopathy Market Access and Reimbursement of Therapies
15. Complement 3 Glomerulopathy Market Drivers
16. Complement 3 Glomerulopathy Market Barriers
17. Complement 3 Glomerulopathy Appendix
18. Complement 3 Glomerulopathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=complement-3-glomerulopathy-market-expected-to-experience-major-growth-by-2034-according-to-delveinsight-novelmed-therapeutics-apellis-pharma-novartis-amyndas-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Complement 3 Glomerulopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma here
News-ID: 4116669 • Views: …
More Releases from ABNewswire
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…
More Releases for Complement
Analysis of the Clinical Trial Pipeline for Complement Inhibitors: 40+ Important …
The global Complement Inhibitors Market is gaining strong momentum as biotechnology and pharmaceutical industries focus on therapies targeting the complement system-an integral part of the immune response. Complement inhibitors are designed to regulate excessive immune activation, which is implicated in rare diseases, autoimmune conditions, and chronic inflammatory disorders. They have become vital therapeutic options in conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration…
Creative Biolabs Announces Complement Testing Services
Creative Biolabs has made new complement function activity testing and hemolytic inhibition assays available to enable therapeutics and immunology research breakthroughs.
New York, USA - March 20, 2025 - The research of complement therapeutics faces great challenges, including the complexity of the complement system, the need for consistent and reproducible assays, and, most importantly, the lack of standardized testing methods. Creative Biolabs, a life science biotech firm focused on developing competitive…
Complement 3 Glomerulopathy Pipeline Therapeutics Assessment Report 2024
DelveInsight's, "Complex regional pain syndromes Pipeline Insight, 2024" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Complex regional pain syndromes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Complement 3…
Complement C5 Global Market Research Report 2025
Complement C5 Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
Access more details about this report at: https://www.research2reports.com/report-medical-devices/complement-c5-market/80992
The report firstly introduced the Complement C5 basics: definitions, classifications, applications and…
Future of Global Complement Deficiency Tests Market : 2016 - 2024
Complement is the group of serum glycoprotein, the part of innate immune system that enhances the ability of antibodies and macrophages to clear the damaged cells and pathogens. Complement also promotes inflammation and aids in enhancing the immune response. The complement system is activated through a cascade. Complement deficiency is a primary immunodeficiency disorder. Deficiency in any component of complement can lead to immunosuppression, infections and sepsis. Clinical indication for…
Autoimmune forms of complement associated kidney disorders
"The field of autoimmune forms of kidney disorders is rapidly progressing and new autoimmune forms and new pathological principles are emerging. Based on similarities among various related kidney disorders, common pathophysiological principles are currently defined. This reveals a spectrum of disorders which is relevant for therapy," Professor Dr. Peter Zipfel and colleagues report.
"Hemolytic uremic syndrome (HUS) and membranproliferative glomerulonephritis (MPGN ore dense deposit disease) represent severe kidney diseases, which…
